Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the
Search jobs 11-Dec-2020 Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS Results show continued efficacy of neratinib in patients with HER2-positive early stage breast cancer LOS ANGELES, Calif., December 11, 2020 / B3C newswire / --Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive early stage breast cancer (eBC) from the Phase III ExteNET trial were presented at the 2020 Virtual San Antonio Breast Cancer S...
Source: pharmiweb.com